|
Name |
Chartarlactam J
|
Molecular Formula | C23H31NO5 | |
IUPAC Name* |
(2S,3S,4aS,7R,8R,8aS)-2,3,4'-trihydroxy-4,4,7,8a-tetramethylspiro[2,3,4a,5,6,7-hexahydro-1H-naphthalene-8,2'-7,8-dihydro-3H-furo[2,3-e]isoindole]-6'-one
|
|
SMILES |
C[C@@H]1CC[C@@H]2[C@@]([C@@]13CC4=C(C=C5C(=C4O3)CNC5=O)O)(C[C@@H]([C@H](C2(C)C)O)O)C
|
|
InChI |
InChI=1S/C23H31NO5/c1-11-5-6-17-21(2,3)19(27)16(26)9-22(17,4)23(11)8-13-15(25)7-12-14(18(13)29-23)10-24-20(12)28/h7,11,16-17,19,25-27H,5-6,8-10H2,1-4H3,(H,24,28)/t11-,16+,17+,19-,22+,23-/m1/s1
|
|
InChIKey |
RUBLIKRGQGISNL-IDWWFARSSA-N
|
|
Synonyms |
Chartarlactam J; CHEMBL3104969
|
|
CAS | NA | |
PubChem CID | 76328315 | |
ChEMBL ID | CHEMBL3104969 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 401.5 | ALogp: | 2.8 |
HBD: | 4 | HBA: | 5 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 99.0 | Aromatic Rings: | 5 |
Heavy Atoms: | 29 | QED Weighted: | 0.535 |
Caco-2 Permeability: | -5.075 | MDCK Permeability: | 0.00000630 |
Pgp-inhibitor: | 0.014 | Pgp-substrate: | 0.963 |
Human Intestinal Absorption (HIA): | 0.021 | 20% Bioavailability (F20%): | 0.811 |
30% Bioavailability (F30%): | 0.105 |
Blood-Brain-Barrier Penetration (BBB): | 0.297 | Plasma Protein Binding (PPB): | 93.31% |
Volume Distribution (VD): | 0.707 | Fu: | 13.26% |
CYP1A2-inhibitor: | 0.174 | CYP1A2-substrate: | 0.637 |
CYP2C19-inhibitor: | 0.033 | CYP2C19-substrate: | 0.347 |
CYP2C9-inhibitor: | 0.39 | CYP2C9-substrate: | 0.742 |
CYP2D6-inhibitor: | 0.485 | CYP2D6-substrate: | 0.262 |
CYP3A4-inhibitor: | 0.212 | CYP3A4-substrate: | 0.21 |
Clearance (CL): | 12.664 | Half-life (T1/2): | 0.53 |
hERG Blockers: | 0.053 | Human Hepatotoxicity (H-HT): | 0.324 |
Drug-inuced Liver Injury (DILI): | 0.055 | AMES Toxicity: | 0.008 |
Rat Oral Acute Toxicity: | 0.948 | Maximum Recommended Daily Dose: | 0.945 |
Skin Sensitization: | 0.917 | Carcinogencity: | 0.227 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.107 |
Respiratory Toxicity: | 0.952 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003009 | 1.000 | D0D2TN | 0.267 | ||||
ENC003012 | 0.816 | D0D1SG | 0.261 | ||||
ENC003259 | 0.785 | D0KR5B | 0.261 | ||||
ENC005396 | 0.773 | D08PIQ | 0.256 | ||||
ENC001965 | 0.729 | D0L2LS | 0.252 | ||||
ENC003014 | 0.691 | D02JNM | 0.248 | ||||
ENC002994 | 0.677 | D04SFH | 0.246 | ||||
ENC002995 | 0.625 | D04VIS | 0.246 | ||||
ENC003789 | 0.625 | D0Y2YP | 0.244 | ||||
ENC003552 | 0.596 | D0Z1FX | 0.243 |